CU CPT 22产品描述：CU CPT 22 is a toll-like receptor 1 and 2 (TLR1/2) inhibitor with an IC₅₀ of 0.58 ?M.IC50 & Target: IC50: 0.58 μM (TLR1/2)^[1]In Vitro: CU CPT 22 is a toll-like receptor 1 and 2 (TLR1/2) inhibitor with an IC₅₀ of 0.58±0.09 ?M. It is demonstrated that CU CPT 22 is able to compete with Pam₃CSK₄ for binding to TLR1/2 with an inhibition constant (K_i) of 0.41±0.07 ?M, which is consistent with its potency observed in the whole cell assay. Increasing the concentration of CU CPT 22 to 6 ?M decreases the anisotropy to background levels. It is found that CU CPT 22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells. CU CPT 22 is found to have no significant cytotoxicity at various concentrations up to 100 ?M in RAW 264.7 cells. The result demonstrates that CU CPT 22 can inhibit about 60% of TNF-αand 95% of IL-1β at 8 ?M^[1].
产品链接：www.medchemexpress.com/CU_CPT_22.html

研究领域：Immunology/Inflammation

靶点：Toll-like Receptor (TLR)

相关产品：TAK-242  |  Chloroquine diphosphate  |  Resiquimod  |  GS-9620  |  Motolimod  |  Imiquimod  |  C29  |  E6446 dihydrochloride  |  Hydroxychloroquine sulfate  |  Atractylenolide I  |  Leonurine  |  Toll-like receptor modulator  |  Gardiquimod trifluoroacetate  |  Procyanidin B1  |  MD2-IN-1  |  



公司介绍：MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库，总部位于美国新泽西，分别在瑞典和上海设有欧洲区子公司和亚洲区总代理，营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商， 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域，PI3K、MAPK等近千个细分靶点，超过4000个活性小分子化合物现货，以及GPCR、API、离子通道等超过20种不同类型的化合物库，同时提供从毫克到千克的专业定制合成服务。
MCE 对每批产品都进行严格的LCMS和NMR检验，其产品已被全球近万名客户广泛使用并发表大量文章、；
MCE 定期增加各领域热门抑制剂、激动剂，不断扩增已有化合物库，以满足*新的科研需求；
数千种产品在上海有充足备货，24-48小时内送达客户；
大量产品提供免费试用装；已为全球多个知名企业、院校构建各种定制型化合物库。

更新时间：2024/1/2 10:10:55